COVID-19 Funding Snapshot for Pharma Developers/Manufacturers

Views as of August 7, 2020

Pharma Developers/Manufacturers

COVID-19 pharmaceutical funding landscape

COVID-19 funding has predominantly

COVID-19 drug development

U.S. funding is spread across

government vaccine supply deals

Though funding appears

Select funding deals across

US public deals with disclosed

US public deals with disclosed

Ex-US public deals

with disclosed values

Foundation deals with disclosed

Industry deals with disclosed

COVID-19 funding deals disclaimer

Contributing authors:

Tony Stripling, Associate Consultant
Sean Saunders, Life Sciences Speciaist
Jennifer Henry, Associate Consultant
Patrick Marquet, Associate

Related Insights

Executive Insights

Life Sciences & Pharma

Oncology BD&L: Winning in an Increasingly Competitive Environment

September 12, 2024

Published Articles

Data & Analytics

Use Data and Analytics to Create Your Strategy, Not Just Drive It: Why Critical Decisions…

July 23, 2024

Life Sciences & Pharma

Cost and Reimbursement Assessment for a Biopharmaceutical Company

May 7, 2024

A large biopharmaceutical company developing chimeric antigen receptor T-cell (CAR-T) therapies

Biotech and Pharmaceuticals

Reimbursement Assessment for a Therapy for Hemodialysis Patients

May 3, 2024

A biopharmaceutical company with a novel treatment of chronic kidney disease-associated pruritus asked L.E.K. to assess the potential risk of bundling of…

Executive Insights

Diagnostics, Tools and Personalized Medicine

Commercial Excellence in Life Sciences Tools and Services Companies

April 8, 2024

Executive Insights

Contract/Pharma Services

Unlocking Clinical Trial Success: Strategic Coverage of Patient Care

February 6, 2024